Polar Capital Holdings PLC Mirati Therapeutics, Inc. Transaction History

Polar Capital Holdings PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $206,836 - $411,846	2,728 Added 10.23%	29,390 $2.42 Million
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $4.48 Million - $6.46 Million	-33,930 Reduced 56.0%	26,662 $3.91 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $213,918 - $287,291	1,619 Added 2.75%	60,592 $10.7 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $2.73 Million - $3.41 Million	18,973 Added 47.43%	58,973 $9.53 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $1.59 Million - $2.22 Million	-10,000 Reduced 20.0%	40,000 $6.85 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $8.1 Million - $12 Million	50,000 New	50,000 $11 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.